American Association for Cancer Research
Browse

Supplementary Table S1-S20 from Mutant U2AF1-Induced Mis-Splicing of mRNA Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia

Download (2.31 MB)
dataset
posted on 2024-05-15, 07:20 authored by Peng Jin, Xiaoling Wang, Qiqi Jin, Yi Zhang, Jie Shen, Ge Jiang, Hongming Zhu, Ming Zhao, Dan Wang, Zeyi Li, Yan Zhou, Wenzhu Li, Wei Zhang, Yabin Liu, Siyang Wang, Wen Jin, Yuncan Cao, Guangying Sheng, Fangyi Dong, Shishuang Wu, Xiaoyang Li, Zhen Jin, Mengke He, Xiaxin Liu, Luonan Chen, Yunxiang Zhang, Kankan Wang, Junmin Li

Supplementary Table S1-S20

Funding

National Key Research and Development Program of China (NKPs)

National Natural Science Foundation of China (NSFC)

China Postdoctoral Science Foundation (China Postdoctoral Foundation Project)

Medical-Engineering Cross Foundation of Shanghai Jiao Tong University

History

ARTICLE ABSTRACT

Patients with primary refractory acute myeloid leukemia (AML) have a dismal long-term prognosis. Elucidating the resistance mechanisms to induction chemotherapy could help identify strategies to improve AML patient outcomes. Herein, we retrospectively analyzed the multiomics data of more than 1,500 AML cases and found that patients with spliceosome mutations had a higher risk of developing refractory disease. RNA splicing analysis revealed that the mis-spliced genes in refractory patients converged on translation-associated pathways, promoted mainly by U2AF1 mutations. Integrative analyses of binding and splicing in AML cell lines substantiated that the splicing perturbations of mRNA translation genes originated from both the loss and gain of mutant U2AF1 binding. In particular, the U2AF1S34F and U2AF1Q157R mutants orchestrated the inclusion of exon 11 (encoding a premature termination codon) in the eukaryotic translation initiation factor 4A2 (EIF4A2). This aberrant inclusion led to reduced eIF4A2 protein expression via nonsense-mediated mRNA decay. Consequently, U2AF1 mutations caused a net decrease in global mRNA translation that induced the integrated stress response (ISR) in AML cells, which was confirmed by single-cell RNA sequencing. The induction of ISR enhanced the ability of AML cells to respond and adapt to stress, contributing to chemoresistance. A pharmacologic inhibitor of ISR, ISRIB, sensitized U2AF1 mutant cells to chemotherapy. These findings highlight a resistance mechanism by which U2AF1 mutations drive chemoresistance and provide a therapeutic approach for AML through targeting the ISR pathway. U2AF1 mutations induce the integrated stress response by disrupting splicing of mRNA translation genes that improves AML cell fitness to enable resistance to chemotherapy, which can be targeted to improve AML treatment.